Prehypertension and the Cardiometabolic Syndrome
Approaches to DASH eating plan and increased engagement in physical activity have shown to effectively lower BP and thus are recommended as the first choice for prehypertension management.
Individuals with BP in the upper range of prehypertension (130–139/85–89 mmHg) have a significantly higher risk for cardiovascular disease (CVD).
Pharmacological antihypertensive treatment, specifically trials assessing renin-angiotensin system blockers, has also demonstrated good efficacy and safety.
Numerous studies have shown the relative risk of progression to incident hypertension can be reduced by 20% with intensive lifestyle interventions and by 34–66% with single antihypertensive drug treatment.
More recent research has focused on early detection of additional risk factors among them serum C3 and serum uric acid that may serve as biomarkers in high-risk individuals to improve primary prevention of prehypertension and prediabetes.
KeywordsComplement C3 Serum uric acid Trophy study Attica study Impaired t-PA
- 3.Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet. 2001;358(9294):1682–6.Google Scholar
- 5.Vasan RS, Larson MG, Leip EP, Evans JC, O’donnell CJ, Kannel WB, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001;345(18):1291–7.Google Scholar
- 10.Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. The Trials of Hypertension Prevention Collaborative Research Group. Arch Intern Med. 1997;157(6):657–67.Google Scholar
- 19.Lüders S, Schrader J, Berger J, Unger T, Zidek W, Böhm M, et al. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure—a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens. 2008;26(7):1487–96.PubMedGoogle Scholar
- 21.Julius S, Kaciroti N, Egan BM, Nesbitt S, Michelson EL, Trial of Preventing Hypertension (TROPHY) Investigators. TROPHY study: outcomes based on the seventh report of the joint National Committee on hypertension definition of hypertension. J Am Soc Hypertens. 2008;2(1):39–43.Google Scholar
- 22.Williams SA, Michelson EL, Cain VA, Yang M, Nesbitt SD, Egan BM, et al. An evaluation of the effects of an angiotensin receptor blocker on health-related quality of life in patients with high-normal blood pressure (prehypertension) in the trial of preventing hypertension (TROPHY). J Clin Hypertens. 2008;10(6):436–42.Google Scholar
- 25.Cordero A, Laclaustra M, León M, Grima A, Casasnovas JA, Luengo E, et al. Prehypertension is associated with insulin resistance state and not with an initial renal function impairment: a Metabolic Syndrome in Active Subjects in Spain (MESYAS) Registry substudy. Am J Hypertens. 2006;19(2):189–96.PubMedGoogle Scholar
- 37.Patil SG, Aithala M, Das KK. Evaluation of arterial stiffness in elderly with prehypertension. Indian J Physiol Pharmacol. 2015;59(1):16–22.Google Scholar
- 38.Tomiyama H, Yamashina A. Arterial stiffness in prehypertension: a possible vicious cycle. J Cardiovasc Transl Res. 2012;5(3):280–6.Google Scholar